Stock Market News
Tissue Regenix launches new operating division for 'DermaPure'
Regenerative medical devices company Tissue Regenix Group announced the launch of a new operating division on Monday - 'TRX BioSurgery'.
The AIM-traded firm said 'DermaPure', a decellularised, room-temperature stable dermal allograft, would be the flagship product under the TRX BioSurgery division.
Currently commercialised under Tissue Regenix Wound Care, which would begin operating as 'TRX BioSurgery', DermaPure had proven successful in multiple surgical applications.
Due to DermaPure's impressive single application clinical outcomes, the board said it had been adopted by surgeons within the acute surgical, wound reconstruction, and traditional advanced wound care markets.
In particular, DermaPure said it had seen "significant" uptake in the orthopaedic trauma and urogynaecology segments, where treatment innovation was in high demand.
In order to further expand the opportunity, Tissue Regenix said it had entered an exclusive distribution partnership with ARMS Medical - a specialist distributor in the urogynaecology segment.
The multi-year agreement would give ARMS Medical exclusive rights to distribute DermaPure to hospitals and surgeons throughout the United States for use in urology and gynecology procedures.
Tissue Regenix said the partnership would allow its direct sales force to maintain their focus on soft tissue regeneration in the wound, plastics, orthopaedics and general surgery markets.
"We are excited to announce the launch of the BioSurgery division," said CEO Steve Couldwell.
"Progressing from traditional wound care clinical settings to surgical applications is a natural evolution for DermaPure, which has proven to be clinically efficient in just a single application.
"Our partnership with ARMS Medical, who are known for bringing innovation to women's pelvic health solutions, allows us to leverage their strong relationships with key opinion leaders in the urogynaecology space to further access this market, whilst also maintaining commercial focus in our other key areas."
The AIM-traded firm said 'DermaPure', a decellularised, room-temperature stable dermal allograft, would be the flagship product under the TRX BioSurgery division.
Currently commercialised under Tissue Regenix Wound Care, which would begin operating as 'TRX BioSurgery', DermaPure had proven successful in multiple surgical applications.
Due to DermaPure's impressive single application clinical outcomes, the board said it had been adopted by surgeons within the acute surgical, wound reconstruction, and traditional advanced wound care markets.
In particular, DermaPure said it had seen "significant" uptake in the orthopaedic trauma and urogynaecology segments, where treatment innovation was in high demand.
In order to further expand the opportunity, Tissue Regenix said it had entered an exclusive distribution partnership with ARMS Medical - a specialist distributor in the urogynaecology segment.
The multi-year agreement would give ARMS Medical exclusive rights to distribute DermaPure to hospitals and surgeons throughout the United States for use in urology and gynecology procedures.
Tissue Regenix said the partnership would allow its direct sales force to maintain their focus on soft tissue regeneration in the wound, plastics, orthopaedics and general surgery markets.
"We are excited to announce the launch of the BioSurgery division," said CEO Steve Couldwell.
"Progressing from traditional wound care clinical settings to surgical applications is a natural evolution for DermaPure, which has proven to be clinically efficient in just a single application.
"Our partnership with ARMS Medical, who are known for bringing innovation to women's pelvic health solutions, allows us to leverage their strong relationships with key opinion leaders in the urogynaecology space to further access this market, whilst also maintaining commercial focus in our other key areas."
Related share prices |
---|
Tissue Regenix Group (TRX) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price